메뉴 건너뛰기




Volumn 29, Issue SUPPL. 3, 2014, Pages

Patient-reported outcomes in clinical trials of rare diseases

Author keywords

patient reported outcome; quality of life; rare disease

Indexed keywords

CLINICAL TRIAL (TOPIC); HUMAN; OUTCOME ASSESSMENT; RARE DISEASES;

EID: 84905900312     PISSN: 08848734     EISSN: 15251497     Source Type: Journal    
DOI: 10.1007/s11606-014-2892-z     Document Type: Review
Times cited : (49)

References (17)
  • 2
    • 79551478191 scopus 로고    scopus 로고
    • Validation of the serial use of the Myelofibrosis Symptom Assessment Form (MF-SAF) for measuring symptomatic improvement: Performance in 86 myelofibrosis patients on INCB018424 clinical trial
    • Mesa RA, Kantarjian H, Tefferi A, et al. Validation of the serial use of the Myelofibrosis Symptom Assessment Form (MF-SAF) for measuring symptomatic improvement: performance in 86 myelofibrosis patients on INCB018424 clinical trial. Blood. 2009;114:3917-3917.
    • (2009) Blood , vol.114 , pp. 3917-3917
    • Mesa, R.A.1    Kantarjian, H.2    Tefferi, A.3
  • 3
    • 79551478191 scopus 로고    scopus 로고
    • Validation of the serial use of the Myelofibrosis Symptom Assessment Form (MF-SAF) for measuring symptomatic improvement: Performance in 86 myelofibrosis patients on INCB018424 clinical trial
    • Mesa RA, Kantarjian H, Tefferi A, et al. Validation of the serial use of the Myelofibrosis Symptom Assessment Form (MF-SAF) for measuring symptomatic improvement: performance in 86 myelofibrosis patients on INCB018424 clinical trial. Blood. 2009;114:3917-3917.
    • (2009) Blood , vol.114 , pp. 3917-3917
    • Mesa, R.A.1    Kantarjian, H.2    Tefferi, A.3
  • 4
    • 84893504789 scopus 로고    scopus 로고
    • New Frontiers in Patient-Reported Outcomes: Adverse Event Reporting, Comparative Effectiveness, and Quality Assessment
    • Nov 20. [Epub ahead of print]
    • Basch E. New Frontiers in Patient-Reported Outcomes: Adverse Event Reporting, Comparative Effectiveness, and Quality Assessment. Annu Rev Med. 2013 Nov 20. [Epub ahead of print].
    • (2013) Annu Rev Med
    • Basch, E.1
  • 6
    • 84874371892 scopus 로고    scopus 로고
    • Reporting of patient-reported outcomes in randomized trials: The CONSORT PRO extension
    • CONSORT PRO Group
    • Calvert M, Blazeby J, Altman DG, Revicki DA, Moher D, Brundage MD, CONSORT PRO Group. Reporting of patient-reported outcomes in randomized trials: the CONSORT PRO extension. JAMA. 2013;309(8):814-22.
    • (2013) JAMA , vol.309 , Issue.8 , pp. 814-822
    • Calvert, M.1    Blazeby, J.2    Altman, D.G.3    Revicki, D.A.4    Moher, D.5    Brundage, M.D.6
  • 7
    • 84880222871 scopus 로고    scopus 로고
    • National Quality Forum January 10, Avai lable at: last accessed 4/26/14
    • National Quality Forum. Patient-reported outcomes (PROs) in performance measurement. January 10, 2013. Avai lable at: www.qualityforum.org/Projects/n-r/ Patient-Reported-Outcomes/Patient-Reported-Outcomes.aspx, last accessed 4/26/14.
    • (2013) Patient-reported Outcomes (PROs) in Performance Measurement
  • 8
    • 84880166205 scopus 로고    scopus 로고
    • Patient-reported outcomes-based performance measures
    • Basch E, Torda P, Adams K. Patient-reported outcomes-based performance measures. JAMA. 2013;310(2):139-40.
    • (2013) JAMA , vol.310 , Issue.2 , pp. 139-140
    • Basch, E.1    Torda, P.2    Adams, K.3
  • 10
    • 84877056690 scopus 로고    scopus 로고
    • last accessed 4/26/14
    • International Society for Pharmacoeconomics and Outcomes Research. ISPOR Good Practices for Outcomes Research Index. http://www.ispor.org/workpaper/ practices-index.asp, last accessed 4/26/14.
    • ISPOR Good Practices for Outcomes Research Index
  • 12
    • 79960259603 scopus 로고    scopus 로고
    • Patterns of reporting health-related quality of life outcomes in randomized clinical trials: Implications for clinicians and quality of life researchers
    • Brundage M, Bass B, Davidson J, Queenan J, Bezjak A, Ringash J, Wilkinson A, Feldman-Stewart D. Patterns of reporting health-related quality of life outcomes in randomized clinical trials: implications for clinicians and quality of life researchers. Qual Life Res. 2011;20(5):653-64.
    • (2011) Qual Life Res , vol.20 , Issue.5 , pp. 653-664
    • Brundage, M.1    Bass, B.2    Davidson, J.3    Queenan, J.4    Bezjak, A.5    Ringash, J.6    Wilkinson, A.7    Feldman-Stewart, D.8
  • 13
    • 84905899988 scopus 로고    scopus 로고
    • Addressing Content Validity of PRO Measures: The Unique Case of Rare Diseases
    • http://www.ispor.org/workpaper/practices-index.asp last accessed 4/26/14
    • Leidy, N.K. Addressing Content Validity of PRO Measures: The Unique Case of Rare Diseases. EveryLife Foundation, Workshop 2: Clinical Evaluation of Rare Disease Treatments. June 14 -15, 2011, Washington DC. http://www. everylifefoundation.org/wp-content/uploads/images/workshopseries/ 13-Leidy-Addressing-Content-Validity-of-PROS802Measures.pdf, http://www.ispor.org/workpaper/practices-index.asp, last accessed 4/26/14.
    • Workshop 2: Clinical Evaluation of Rare Disease Treatments. June 14 -15, 2011, Washington DC
    • Leidy, N.K.1
  • 15
    • 84879406265 scopus 로고    scopus 로고
    • Pediatric patient-reported outcome instruments for research to support medical product labeling: Report of the ISPOR PRO good research practices for the assessment of children and adolescents task force
    • Matza LS, Patrick D, Riley AW, et al. Pediatric patient-reported outcome instruments for research to support medical product labeling: Report of the ISPOR PRO good research practices for the assessment of children and adolescents task force. Value Health. 2013;16:461-79.
    • (2013) Value Health , vol.16 , pp. 461-479
    • Matza, L.S.1    Patrick, D.2    Riley, A.W.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.